This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| BDNF | |
|---|---|
| Name | Brain-derived neurotrophic factor |
| Organism | Homo sapiens |
| Family | Neurotrophin |
BDNF Brain-derived neurotrophic factor is a member of the neurotrophin family that supports neuronal survival, growth, and synaptic modulation. It was characterized through biochemical and molecular studies that involved multiple laboratories and informed work across neuroscience institutes, pharmacology units, and clinical centers. Research on BDNF connects to investigations by universities, hospitals, and consortia focused on neurodegeneration, psychiatry, and developmental biology.
The BDNF protein is synthesized as a precursor, proBDNF, and processed to mature BDNF, with characteristic tertiary folding similar to other neurotrophins studied alongside nerve growth factor in laboratories at institutions like Harvard University, Massachusetts Institute of Technology, Stanford University, University of Oxford, and University of Cambridge. The human BDNF gene resides on chromosome 11 and exhibits multiple promoters and splice variants discovered in collaborations involving researchers from National Institutes of Health, Cold Spring Harbor Laboratory, Salk Institute, Max Planck Society, and Johns Hopkins University. Structural insights derived from crystallography and biochemical assays were reported by teams connected to European Molecular Biology Laboratory, Rockefeller University, University of California, San Francisco, University of Pennsylvania, and Yale University. Comparative genomic analyses referencing data from Broad Institute, Wellcome Trust Sanger Institute, National Center for Biotechnology Information, European Bioinformatics Institute, and DNA Data Bank of Japan placed the BDNF locus in evolutionary context with studies involving University of Tokyo, Peking University, Seoul National University, University of Toronto, and McGill University.
BDNF exerts effects primarily through the tropomyosin receptor kinase B, with signaling cascades overlapping pathways characterized in work at University College London, Imperial College London, Columbia University, Duke University, and University of California, Los Angeles. Downstream cascades include MAPK/ERK, PI3K/Akt, and PLCγ routes that were delineated through experiments at California Institute of Technology, ETH Zurich, Karolinska Institutet, University of Freiburg, and École Polytechnique Fédérale de Lausanne. Cross-talk with glutamatergic and GABAergic systems has been examined in laboratories affiliated with McLean Hospital, Massachusetts General Hospital, Mayo Clinic, Cleveland Clinic, and Karolinska University Hospital. Signaling interactions inform synaptic potentiation and depression phenomena investigated with methods developed at Cold Spring Harbor Laboratory, Max Planck Institute of Neurobiology, Riken, Institut Pasteur, and Weizmann Institute of Science.
BDNF expression is activity-dependent and regulated by neuronal firing patterns, epigenetic mechanisms, and hormone signaling studied across groups at University of California, Berkeley, Princeton University, University of Chicago, Northwestern University, and Cornell University. Promoter-specific regulation involves transcription factors characterized by teams at Massachusetts Eye and Ear Infirmary, The Rockefeller University, Scripps Research, Mount Sinai Hospital, and Vanderbilt University Medical Center. Post-transcriptional control via microRNAs and RNA-binding proteins was explored in collaborations including Università di Bologna, University of Barcelona, University of Milan, University of Bologna, and King's College London. Environmental and systemic modulators such as exercise, stress, and diet have been investigated in clinical and population studies by centers like University of Sydney, University of Melbourne, University of Copenhagen, University of Amsterdam, and McMaster University.
BDNF guides neuronal differentiation, dendritic arborization, and synaptogenesis with developmental roles reported by pediatric and developmental neuroscience groups at Children's Hospital Boston, Great Ormond Street Hospital, Boston Children's Hospital, Royal Children's Hospital, and Hospital for Sick Children. Long-term potentiation and experience-dependent plasticity involving BDNF were described in classic and contemporary studies from laboratories at Princeton University, Columbia University, Yale University, University of California, San Diego, and University of Edinburgh. The molecule's involvement in critical period regulation and cortical map plasticity was elucidated in experiments affiliated with Stanford University, UC Berkeley, University of Washington, University of Texas Southwestern Medical Center, and University of Minnesota. Animal model work spanning Massachusetts Institute of Technology, Johns Hopkins University, University of Pennsylvania, University of Cambridge, and University of Oxford informed translational hypotheses linking development to adult plasticity.
Altered BDNF signaling has been associated with neuropsychiatric and neurodegenerative conditions, with clinical studies conducted at institutions including Mayo Clinic, Cleveland Clinic, Mount Sinai Hospital, Massachusetts General Hospital, and Johns Hopkins Hospital. Associations have been explored in cohorts studied by National Institutes of Health, European Commission, World Health Organization, Wellcome Trust, and Bill & Melinda Gates Foundation-supported projects. Specific links to depression, schizophrenia, bipolar disorder, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, autism spectrum disorders, and epilepsy have been reported in publications involving networks at Karolinska Institutet, McGill University, University College London, King's College London, and University of Melbourne. Biomarker studies and genetic association analyses were performed by consortia including ENIGMA, Psychiatric Genomics Consortium, Alzheimer's Disease Neuroimaging Initiative, UK Biobank, and 1000 Genomes Project investigators.
Therapeutic strategies aiming to modulate BDNF signaling include small molecules, gene therapy, monoclonal antibodies, and noninvasive interventions tested in preclinical and clinical settings at Food and Drug Administration, European Medicines Agency, National Institutes of Health Clinical Center, Cleveland Clinic, and Mayo Clinic. Exercise, cognitive training, transcranial magnetic stimulation, and pharmacological enhancers have been trialed by research teams at University of Toronto, University of British Columbia, University of Copenhagen, Karolinska Institutet, and Monash University. Gene delivery and neurotrophin-mimetic development have proceeded in collaborations involving Biogen, Roche, Novartis, GlaxoSmithKline, and Pfizer as well as academic spin-offs from Salk Institute and Cold Spring Harbor Laboratory. Ongoing randomized controlled trials and translational programs are coordinated through partnerships between National Institutes of Health, Wellcome Trust, European Commission Horizon 2020, Canadian Institutes of Health Research, and private biomedical enterprises.
Category:Neurobiology